An overview of progress in the development of obesity medications is provided, including a synthesis of data describing the efficacy and safety of currently available agents and emerging therapeutic options.
Abstract
ABSTRACT This narrative review provides an overview of progress in the development of obesity medications, including a synthesis of data describing the efficacy and safety of currently available agents and emerging therapeutic options. Historically, many obesity medications have been withdrawn from the market due to safety concerns. However, expansion in scientific knowledge of the mechanisms regulating appetite and energy balance has led to the development of medications with greater safety and efficacy. The current generation of injectable incretin analogs, semaglutide and tirzepatide, is associated with mean weight loss in the range of 15%–20% over approximately 12–18 months. These agents confer additional substantial cardiometabolic benefits, including reductions in adverse cardiovascular and kidney outcomes, and improvements in glycaemia, blood pressure, lipid profile and steatohepatitis. As therapeutic options continue to expand, obesity medications are poised to play a critical role in the management of cardiometabolic disease.
Background: The systematic review was done with an objective to assess efficacy and safety of anti-obesity medications (AOMs), FDA-approved and emerging, in various populations (older than 50 years of age, children, and individuals with type 2 diabetes [T2DM]); and to analyze cardiometabolic outcomes. Material and Meth...
K. Ram, Syed Haris Bukhari, Rahul Arora et al.· Acta Medica International· 0 citations
Obesity is a long-term, complex disorder characterised by excessive adiposity that increases the risk of metabolic and cardiovascular diseases. Obesity is a significant health problem, with its prevalence increasing steadily over the last several decades. This rising trend has contributed substantially to the burden of...
Kaushal Navanath Mehetre, J. Dawane· Frontiers in Endocrinology· 0 citations
Introduction: Excessive body weight is a growing problem in Poland and worldwide. Adverse epidemiological trends necessitate the search for effective pharmacological therapies to support behavioral interventions in achieving sustainable therapeutic goals and reducing the risk of metabolic complications of obesity.
Mate...
Aleksandra Wielogórska, Olga Stasiak, Filip Kowalik et al.· International Journal of Inn...· 0 citations
Obesity is now recognized as a chronic, multifactorial, and progressive disease as opposed to mere excess of body weight. It significantly increases the risk of type 2 diabetes, cardiovascular disease, metabolic-associated fatty liver disease, and mental health disorders. 2022 data reveal that nearly 3 billion individu...
S. Atal, Chirag Agrawal, Rahul Gupta et al.· Indian Journal of Pharmacolo...· 0 citations
Obesity is a chronic, multifactorial disease characterized by excessive adiposity and associated with an increased risk of cardiovascular disease, type 2 diabetes, and reduced quality of life. Despite the widespread adoption of lifestyle interventions, long-term weight maintenance remains challenging, highlighting the...
Fnu Zainab, Abdul Haseeb Hasan· Annals of Medicine and Surge...· 0 citations
